Centre for Heart Lung Innovation
St. Paul's Hospital
Room 166 - 1081 Burrard Street
Vancouver, B.C. V6Z 1Y6
Dr. Honglin Luo is a Professor in the UBC Department of Pathology and Laboratory Medicine. She was a Canadian Institutes of Health Research/St. Paul’s Hospital Foundation New Investigator and a Michael Smith Foundation for Health Research Scholar. Dr. Luo was awarded a Canada Foundation for Innovation New Opportunities grant in acquiring cutting-edge infrastructure. Her work on the roles of protein degradation system and host signaling in virus-mediated myocarditis were supported by the Canadian Institutes of Health Research, the Heart & Stroke Foundation of Canada, and the Hospital for Sick Kids Foundation.
Education and Training
- West China University of Medical Sciences MS, Hemodynamics, 1989
- Chongqing Medical University MD, Medicine, 1986
- University of Washington Postdoc, Pathology, 1997-2000
Area of Interest
The focus of Dr. Luo’s main research is to define the molecular and pathogenic determinants of virus-host interactions in enterovirus-induced cardiac and neurodegernative diseases. The ongoing research projects include:
- Understanding the molecular mechanisms of imparied cardiac function in enteroviral myocarditis. This research focuses on the protein quality control system, which includes molecular chaperones and protein degradation pathways (ie. the ubiquitin-proteosome system and autophagy) with the long-term goal of designing effective molecular therapies for this disease.
- Determining the possible role of enteroviral infection in the development of amyotrophic lateral sclerosis (ALS). Dr. Luo's laboratory recently made the exciting discovery that enteroviral infection results in the hallmark molecular and pathological features of ALS. The current project aims to establish and understand the contribution of enteroviral infection in the pathogenesis of ALS and to test whether application of anti-enteroviral drugs can lessen the progression of ALS.
- Developing coxsackievirus B3 (CVB3) as an oncolytic virus for lung cancer treatment. Using cellular and mouse models, Dr. Luo's group recently found that CVB3 is an extremely potent anti-tumor virus that can specifically destroy various types of lung cancer cells with limited effects on normal cells. The present research aims to genetically engineer CVB3 to further enhance its safety and anti-tumor potency for the treatment of lung cancer.